This new White Paper on Immunomic Therapeutics’ expanded technology platform called UNITE™. It chronicles what we have built over the past decade and how we have moved beyond the original design of LAMP for intracellular targeting. UNITE™ is an acronym for Universal Intracellular Targeted Expression. It describes a combination of intracellular and molecular biology methods for enhanced MHC-II presentation combined with potent adjuvant and delivery technologies to provide a unified and complete immune system response.
Immunomic Therapeutics is a privately-held, clinical stage biotech company developing modern DNA and RNA vaccines for allergic diseases and cancers.
At the heart of the company’s science is its patented investigational Lysosomal-Associated Membrane Protein (LAMP) vaccine technology, which was licensed from Johns Hopkins University in 2006. The LAMPvax™ platform is designed to overcome many of the limitations of conventional vaccines, working with the body’s natural biochemistry to stimulate a multi-faceted immune response.
Since then, the company, its programs and its therapeutic areas of focus have expanded, particularly into immuno-oncology, with the addition of new science, patents, and many complementary tools and methods. To reflect that evolution, Immunomic Therapeutics has renamed its flagship platform UNITE™.
UNITE™ captures the platform’s value in immunooncology and beyond, and when deconstructed, reveals an appropriate descriptor: ‘UNiversal Intracellular Targeted Expression.’
Visit www.immunomix.com for more information